Reduction of endothelial dysfunction following VEGF gene therapy

Area of Science:

• Cardiovascular Research
• Gene Therapy
• Angiogenesis

Background:

• Vascular endothelial growth factor (VEGF) is a key angiogenic factor.
• VEGF gene therapy shows promise for improving myocardial perfusion in ischemic conditions.
• VEGF influences endothelial cell proliferation, migration, and nitric oxide synthase (eNOS) activity.

Purpose of the Study:

• To investigate the impact of VEGF gene therapy on coronary endothelium-dependent vasodilation.
• To assess functional changes in the myocardial vascular network post-VEGF gene therapy.

Main Methods:

• Coronary diameter response to intracoronary acetylcholine infusion was measured.
• Patients with end-stage coronary artery disease received VEGF gene therapy or were controls undergoing PTCA.
• Assessments were conducted at baseline and three months post-treatment.

Main Results:

• VEGF gene therapy reduced anginal symptoms in 80% of patients.
• The vasoconstrictive response to acetylcholine shifted towards vasodilation post-therapy.
• Control patients maintained a vasoconstrictive response to acetylcholine.

Conclusions:

• VEGF gene therapy significantly improves the functional characteristics of the myocardial vascular network.
• This therapy holds potential for managing all stages of the atherosclerotic process.